Aditxt Inc

Aditxt, Inc. engages in the development of biotechnologies specifically focused on improving the health of the immune system through immune reprogramming and monitoring. It has a worldwide license for commercializing a nucleic acid-based technology, named Apoptotic DNA Immunotherapy (ADi), which utilizes a novel approach that mimics the way the body naturally induces tolerance to its own tissue. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Richmond, VA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aditxt, Inc. is a biotech innovation company, which engages in the development and commercialization of technologies focusing on monitoring and modulating the immune system. Its innovation portfolio includes Adimune and AditxtScore. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Richmond, VA.

Aditxt Inc (NASDAQ: ADTX) has announced enhancements to its AditxtScore for COVID-19 to include a high-sensitivity neutralizing antibody diagnostic. The multi-dimensional immune response test tracks multiple combinations of antibody responses against several different antigens.

Aditxt's COVID-19 Test To Include Specific Antibodies To Detect Individual Immune Response; Shares Rise

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced enhancements to its AditxtScore™ for COVID-19. A multi-dimensional immune response test that tracks multiple combinations of antibody responses against several different antigens, AditxtScore for COVID-19 has been enhanced to include a high-sensitivity neutralizing antibody diagnostic, which makes it possible to assess th

Aditxt Launches High-Sensitivity Neutralizing Antibody Test to Detect Individual Immune Response to COVID-19

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced the opening of its AditxtScore™ Center in Richmond, VA. This high-capacity, CLIA-validated immune monitoring center will be scalable to process several million complex immune system reports per year. “The opening of the AditxtScore Center is a key step on AditxtScore's path to market, serving as a critical enabler to commercializing

Aditxt Opens its First High-Capacity Immune Monitoring Center in Richmond, VA

Sphere 3D

Vinco Ventures

Globalstar

Gran Tierra Energy

Luokung Technology Corp

MediciNova

New Gold

Pieris Pharma

Qudian

Transocean

Tellurian

US Well Services

Uxin Ltd - ADR

Xeris Biopharma Holdings

These penny stocks are trending right now, here's why The post Best Penny Stocks to Buy Right Now? 15 To Watch In July appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy Right Now? 15 To Watch In July

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditx Therapeutics, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today that Dr. Lauren Chung will join the Aditxt board of directors as an independent director. “As a new independent director of Aditxt's board, Dr. Chung brings deep insights spanning global scientific, investment and business communities, and these experiences strongly complement our future growth goals,”

Aditxt Announces the Appointment of Dr. Lauren Chung to its Board of Directors

MOUNTAIN VIEW, Calif., June 15, 2021 /PRNewswire/ -- Aditx Therapeutics, Inc. ("Aditxt") (NASDAQ: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced that it is set to join the Russell Microcap® Index, effective after the US market opens on June 28, 2021.

Aditxt Set to Join Russell Microcap® Index

Making a penny stocks watchlist for June? Check these 5 Reddit small caps out The post 5 Penny Stocks on Reddit For Your June 2021 Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks on Reddit For Your June 2021 Watchlist

MOUNTAIN VIEW, Calif., May 6, 2021 /PRNewswire/ -- Aditx Therapeutics, Inc. (Aditxt) (the "Company") (Nasdaq: ADTX), a biotech innovation company focused on improving the health of the immune system, today announced that Meridian Health Services Network (Meridian HSN) will offer AditxtScore™ for COVID-19 to its network of healthcare provider partners.

Aditxt Signs Channel Partner Agreement with Meridian HSN to Make AditxtScore™ for COVID-19 Available to its Network of Healthcare Provider Partners

Aditxt to Establish State-of-the-Art Immune Monitoring Center in Richmond, VA

MOUNTAIN VIEW, Calif., April 13, 2021 /PRNewswire/ -- Aditx Therapeutics, Inc. (Aditxt) (the "Company") (Nasdaq: ADTX), a biotech innovation company focused on improving the health of the immune system, today announced that Sunny Uberoi has joined the organization as its Chief Communications Officer.

Aditxt Therapeutics Names Sunny Uberoi as its first Chief Communications Officer

MOUNTAIN VIEW, Calif., April 6, 2021 /PRNewswire/ -- Aditx Therapeutics, Inc. (Aditxt) (the "Company") (Nasdaq: ADTX), a biotech innovation company focused on improving the health of the immune system, today announced that HealthBar will be offering AditxtScore™ for COVID-19 throughout the State of Michigan.

HealthBar Becomes AditxtScore™ Channel Partner to Offer AditxtScore™ for COVID-19 Immunity Status Monitoring to Complement its Concierge and Drive-Thru Testing Services

MOUNTAIN VIEW, Calif., April 1, 2021 /PRNewswire/ -- Aditx Therapeutics, Inc. (Aditxt) (the "Company") (Nasdaq: ADTX), a biotech innovation company focused on improving the health of the immune system, today announced that Collection Sites, LLC will offer AditxtScore™ for COVID-19 through its mobile testing centers.

Collection Sites, LLC Named AditxtScore™ Channel Partner to Offer AditxtScore™ for COVID-19 Immunity Status Monitoring through its Mobile Testing Centers

Aditx Therapeutics Inc (NASDAQ: ADTX) is preparing its therapeutic program for psoriasis for First-In-Human clinical trials by the end of this year. The trials, which are planned to begin in Q4 2021, will evaluate the clinical safety and efficacy of Aditxt's new approach to reprogramming and retraining the immune system.

Aditx Therapeutics Stock Is Trading Higher On Initiating Human Trials With Psoriasis Candidate By 2021

MOUNTAIN VIEW, Calif., March 24, 2021 /PRNewswire/ -- Aditx Therapeutics, Inc. (Aditxt) (the "Company") (Nasdaq: ADTX), a biotech innovation company focused on improving the health of the immune system, today announced that its AditxtReprogrammingTM Therapeutics Division is preparing its therapeutic program for psoriasis for First-In-Human clinical trials.

Aditxt to Initiate First-In-Human Clinical Trials with its Therapeutics Programs in Psoriasis by Year-End

Mountain View, CA, March 04, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a biotech innovation company focused on improving the health of the immune system, today announced that Eazy Testing Inc. will be offering AditxtScore™ for COVID-19 throughout its California locations.

Eazy Testing Inc. Becomes AditxtScore™ Channel Partner, to Offer AditxtScore™ for COVID-19 Immunity Status Monitoring with its Walk-In, Concierge, and Pre-Flight Services

Dr. Tyan Will Lead and Advance Organ Transplantation Therapeutic Program

Immunologist and Clinical Transplant Expert, Dolly B. Tyan, PhD, Joins Aditxt as Senior VP of Clinical Development - Transplantation

Balance Sheet Further Strengthened by Receipt of Additional $3.3 Million from Exercise of Existing Warrants

Aditxt Secures $5 Million Financing to Scale AditxtScore™ Operational Capacity

Shares of ADiTx Therapeutics Inc (NASDAQ: ADTX) are trading at a five-month high Thursday after ADiTx announced it would launch the AditxtScore Immune Monitoring Platform on Feb. 1. The initial application of the platform will be for providing more complete assessment of an individual's infection and immunity status with respect to the SARS-CoV-2 virus.

Why ADiTx Shares Are Rallying To A 5-Month High

News for Aditxt Inc Stock (ADTX)